Skip to main content

Fiscal Wizard · Single-issue tearsheet

SNN / Jun 22, 2026 Run #7665

SNN

Smith & Nephew plc

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Composite verdict

D 32.2 / 100
Bearish setup · Reversal 10 drivers · 3 gates blocking
  • Chaikin Money Flow
  • Fibonacci Retracement
  • Sushi Roll
Consider long put target Δ ~0.70 · ~35 DTE Bearish setup, Grade A → ITM put target

Industry rank 43rd of 141 in Medical Devices

rescore-sweep
Technical synthesisRegime: range
Bull 0%Evidence: High · 20 signals100% Bear
Momentum Bearish 13Mean-reversion Neutral 44

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -79%
Asset value $12.50Earnings power value $11.51Price $30.08

Priced above its no-growth earnings power value ($11.51/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Above average

63.9 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Free Cash Flow Yield 81
Margin of Safety 0
EBITDA Margin 77
OCF to Net Income 0
Greenblatt ROC 77
Inventory Turnover 0

Technicals Bearish

0.5 / 100

Bearish setup leads (Chaikin Money Flow, Fibonacci Retracement, Sushi Roll); bulls gated by guards. · 43 signals shown.

Strongest
Weakest
Chaikin Money Flow 10
Fibonacci Retracement 12
Vortex Signal 13

Risk Gates

3 blocking 2 caution

3 guards active, 21 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Debt-to-Assets Caution

High debt-to-assets blocks bullish signals — balance-sheet leverage risk.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SNN.